team banner.jpg

Hanadie Yousef is a trained stem cell biologist and neurobiologist with a focus on the mechanisms of aging, with pending and issued patents, several publications, a BS from Carnegie Mellon University (CMU), a PhD from UC Berkeley, a 4-year postdoctoral fellowship at Stanford School of Medicine, experience leading research teams, and has worked in R&D at Regeneron and Genentech.    Yousef began doing biomedical research at the age of 16, when she interned locally at a pharmaceutical company in New York where she grew up, Regeneron, to conduct research on gene therapy and cancer. It was at this time that Yousef fell in love with drug discovery and development and knew she wanted to dedicate the rest of her life to this pursuit. She skipped a grade and attended CMU to study chemistry and continue her passion in scientific research. She returned to Regeneron to continue her research during winter and summer internships for 5 years (2003-2008). During her undergraduate studies at CMU, Yousef did a research honors thesis in the Kaminski lab at the University of Pittsburgh Medical Center, where she elucidated molecular mechanisms driving idiopathic pulmonary lung fibrosis.    In graduate school in the Schaffer and Conboy labs at UC Berkeley (2008-2013), Dr. Yousef studied the role of adult stem cells in the biology of aging and developed methods for tissue rejuvenation in brain and muscle. She published 4 first-author papers, a research perspective,and has an issued patent and a patent application based on her discoveries.

Katelyn busse
research associate II

Katelyn Busse is a Research Associate II at Juvena Therapeutics, where she focuses on screening and validation of drug candidates using in vitro high throughput screening. Skilled in both muscle biology and drug discovery, she is working on perfecting aspects of our high throughput screening pipeline, to help discover new drug candidates that rejuvenate aged stem cells. Katelyn joined Juvena Therapeutics in April of 2019.

Katelyn started her biotech R&D career during her undergraduate studies at Rochester Institute of Technology. While earning her Bachelors of Science in Biomedical Engineering, she completed full-time co-ops at Janssen Pharmaceuticals, Wake Forest Institute for Regenerative Medicine, and the NanoBio Device Lab at Rochester Institute of Technology. After graduation, she moved to San Diego to begin working with Genea Biocells where she spent 3 years improving the skeletal muscle differentiation media suite and developing secondary assays for use in their disease pipelines based on human embryonic stem cell derived skeletal muscle. Katelyn and her team earned the FDA’s Orphan Drug Designation for a lead compound in the treatment of Facioscapulohumeral Muscular Dystrophy (FSHD).

For fun, Katelyn likes to ride her bike and read on her kindle. Whenever possible, she enjoys a great cup of coffee or discovering new wines.